Bayer invests in new veterinary research facility
Bayer invests in new veterinary research facility
• Focus on chemistry and
formulation
• Research to benefit
livestock
• Science & Innovation Minister attends
opening
Auckland, 30 August, 2013 - Bayer’s Auckland-based Centre for Innovation and Development (CID) today opened a new research facility, which will play a key part in improving the health of farm and pet animals.
Located at Bayer’s Glenfield site, the facility replaces a smaller laboratory at its Manukau production site.
The new, larger facility, which includes a laboratory, will focus on making veterinary medicines more effective through developing new formulations for the local market and region. It is staffed with an international team of formulation experts, analysts and technicians.
Bayer New Zealand’s head of animal health, Derek Bartlett, says “the facility will make important contributions to improving the health of animals, particularly in the areas of mastitis, reproduction and metabolic health management.
“By improving our research capacity with a new laboratory, we will be able to better meet the growing needs of the animal health market.”
Bayer’s CID head Wayne Leech says improving medicines is an important, but often over-looked, means of improving life on the farm.
“This new laboratory demonstrates Bayer’s commitment to providing veterinary solutions to meet the special needs of New Zealand and regional markets.
“For example, we will be looking at how to make medicines last longer in the animal as well as combining two medicines given to an animal separately into a single dose medicine.
“These are both examples of how improving
medicines can make life easier for the veterinarian, farmer
and ultimately the animal.”
Attending the opening
ceremony were Science and Innovation Minister Steven Joyce,
Bayer ANZ CEO Dr Jackie Applegate and various Bayer global
research heads from Europe, including Bayer’s head of
global animal health development Dr Douglas
Hutchens.
“This new laboratory represents Bayer’s continued commitment to developing veterinary solutions,” says Dr Hutchens. “By expanding the work of the Centre for Innovation and Development, we are investing in innovations that will benefit veterinarians and farmers globally.”
About Bayer New Zealand’s Centre for
Innovation and Development
The Centre is made up of
35 specialists, including veterinarians, pharmacists,
pharmacologists, analytical chemists, regulatory affairs
experts, patent attorneys and statisticians. It has four
functional units: Formulation and Development; Regulatory
Affairs for New Zealand and Asia Pacific; Intellectual
Property and Clinical Studies. Each of these areas is
brought together through project management to deliver new
or improved products. CID is now seen as a fully integrated
part of the Bayer global development team and features
regularly in global development initiatives.
About
Bayer HealthCare
The Bayer Group is a global
enterprise with core competencies in the fields of health
care, agriculture and high-tech materials. Bayer HealthCare,
a subgroup of Bayer AG with annual sales of EUR 18.6 million
(2012), is one of the world’s leading, innovative
companies in the healthcare and medical products industry
and is based in Leverkusen, Germany. The company combines
the global activities of the Animal Health, Consumer Care,
Medical Care and Pharmaceuticals divisions. Bayer
HealthCare’s aim is to discover, develop, manufacture and
market products that will improve human and animal health
worldwide. Bayer HealthCare has a global workforce of 55,300
employees (Dec 31, 2012) and is represented in more than 100
countries. More information at www.healthcare.bayer.com.
Find more information about Bayer HealthCare Animal Health, New Zealand, at www.bayeranimal.co.nz
Forward-Looking
Statements
This release may contain forward-looking
statements based on current assumptions and forecasts made
by Bayer Group or subgroup management. Various known and
unknown risks, uncertainties and other factors could lead to
material differences between the actual future results,
financial situation, development or performance of the
company and the estimates given here. These factors include
those discussed in Bayer’s public reports which are
available on the Bayer website at www.bayer.com.The company assumes no
liability whatsoever to update these forward-looking
statements or to conform them to future events or
developments.
ENDS